Syndax Pharmaceuticals announced a collaboration to expand global access to Revuforj while reporting strong commercial performance for its two marketed products, with Revuforj generating $125 million and Niktimvo $152 million in the first 11 months of sales.
The FDA approved Tecvayli plus Darzalex Faspro for relapsed/refractory multiple myeloma in March 2026, and Darzalex Faspro-based quadruplet D-VRd for newly diagnosed transplant-ineligible patients in January 2026.
Eli Lilly announced the acquisition of Orna Therapeutics for up to $2.4 billion on February 9, 2026, gaining access to proprietary circular RNA technology and an "in vivo" CAR-T platform for immunology and oncology applications.
The FDA approved the combination of acalabrutinib and venetoclax as the first all-oral, fixed-duration regimen for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma, based on Phase 3 AMPLIFY trial results.
West Virginia University Cancer Institute has dosed the first patient in a phase 1/2 trial evaluating subcutaneous blinatumomab for CD19-positive mixed-phenotype acute leukemia, a rare disease with no FDA-approved therapies. The first patient achieved complete remission after one cycle.
FDA approves AstraZeneca's Calquence plus venetoclax as first all-oral, 14-month fixed-duration regimen for first-line chronic lymphocytic leukemia, with 77% of patients progression-free at three years in Phase III trial.
The FDA has approved the combination of acalabrutinib and venetoclax as the first all-oral, fixed-duration BTK inhibitor-based regimen for previously untreated adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
The FDA has approved the combination of Venclexta (venetoclax) plus acalabrutinib as the first all-oral, fixed-duration regimen for previously untreated adults with chronic lymphocytic leukemia, based on Phase III AMPLIFY study results.
Roche announced positive Phase III MAJESTY trial results showing Gazyva achieved significantly higher complete remission rates at two years versus tacrolimus in primary membranous nephropathy, with no new safety signals identified.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06982274 |
Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia |
RECRUITING | PHASE2 |
| NCT06928909 |
Leukemia Adapted Protocol |
RECRUITING | |
| NCT06379282 |
Investigating the Role of Energy Balance Modification on Health Responses in Chronic Lymphocytic Leukaemia |
RECRUITING | NA |
| NCT06260891 |
Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial |
RECRUITING | PHASE2 |
| NCT06153797 |
A Positive Psychology Based Intervention (PATH-C) for Caregivers of HSCT Survivors |
ACTIVE_NOT_RECRUITING | NA |
| NCT05998824 |
COVID-19 Vaccination Hesitancy in Adults With Sickle Cell Disease |
COMPLETED | NA |
| NCT05507827 |
Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT05451940 |
Hydroxyurea and EPO in Sickle Cell Disease |
COMPLETED | PHASE1/PHASE2 |
| NCT05434598 |
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS |
RECRUITING | NA |
| NCT05139992 |
COVID-19 Vaccine Response in Sickle Cell Disease |
COMPLETED |
